35.2 Definitions D Definition: Brachytherapy source N/A 35.2 Definitions D Definition: Clients address N/A 35.2 Definitions D Definition: Dedicated check source N/A 35.2 Definitions D Definition: Dentist N/A 35.2 Definitions D Definition: High dose-rate remote afterloader N/A 35.2 Definitions D Definition: Low dose-rate afterloader N/A 35.2 Definitions D Definition: Management N/A 35.2 Definitions D Definition: Manual Brachytherapy N/A 35.2 Definitions D Definition: Medical event N/A 35.2 Definitions D Definition: Medical institution N/A 35.2 Definitions C Definition:
35.27, unless prohibited by license 35.12 Application for license, amendment, or renewal D N/A N/A 35.13 License amendments D N/A N/A 35.14 Notifications D N/A N/A 35.15 Exemptions regarding Type A specific licenses of scope D N/A N/A 35.18 License issuance D N/A N/A 35.19 Specific exemptions D N/A N/A 35.24 (b) Authority and responsibilities for the radiation protection program H&S (b) A licensee's management shall appoint a Radiation Safety Officer, who agrees, in writing, to be responsible for implementing the radiation protection program. The licensee, through the Radiation Safety Officer, shall
(2) Calibrate two separated readings on each scale or decade that will be used to show compliance; and (b) A licensee may not use survey instruments if the difference between the indicated exposure rate and the calculated exposure rate is more than 20 percent. 35.63 Determination of dosages of unsealed byproduct material for medical use H&S (a) A licensee shall determine and record the activity of each dosage before medical use. (b) For a unit dosage, this determination must be made by (1) Direct measurement of radioactivity; or (2) A decay correction, based on the activity or activity concentration determined by (i) A manufacturer or preparer licensed under 32.72 of this chapter or equivalent requirements; or (ii) An NRC or Agreement licensee for use in research in accordance with a Radioactive Drug Research protocol or an Investigational New Drug (IND) protocol accepted by FDA.
activities not likely to cause doses exceeding 5 mSv (0.5 rem). (b) A licensee shall provide the released individual, or the individual's parent or guardian, with instructions, including written instructions, on actions recommended to maintain doses to other individuals as low as is reasonably achievable if the total effective dose equivalent to any other individual is likely to exceed 35.80 Provision of mobile medical service H&S for States that authorize activity D otherwise (a)(2) instruments used to measure the activity of unsealed byproduct material for proper function before medical use at each client's address or on each day of use, whichever is more frequent. At a minimum, the check for proper function required by this paragraph must include a constancy check; (a)(3) Check survey instruments for proper operation with a dedicated check source before use at each client's address; (b) A mobile medical service may not have byproduct material delivered from the manufacturer or the distributor to the client unless the client has a license
accepted by the FDA provided the requirements of 35.49(a) are met. 35.404 Surveys after source implant and removal H&S (a) Immediately after implanting sources in a patient or a human research subject, the licensee shall make a survey to locate and account for all sources that have not been implanted. (b) Immediately after removing the last temporary implant source from a patient or a human research subject, the licensee shall make a survey of the patient or the human research subject with a radiation detection survey instrument to confirm that all sources have been removed. 35.406 Brachytherapy sources accountability H&S (a) A licensee shall maintain accountability at all times for all brachytherapy sources in storage or use. (b) As soon as possible after removing sources from a patient or a human research subject, a licensee shall return brachytherapy sources to a secure storage area. 35.410 Safety instruction H&S In addition to the requirements of 19.12 of this chapter,
(1) Before the first medical use of the unit; (2) Before medical use under the following conditions (i) Whenever spot-check measurements indicate that the output differs by more than 5 percent from the output obtained at the last full calibration corrected mathematically for radioactive decay; (ii) Following replacement of the sources or following reinstallation of the stereotactic radiosurgery unit in a new location; and (iii) Following any repair of the gamma stereotactic radiosurgery unit that includes removal of the sources or 35.642 Periodic for teletherapy units H&S (a) A licensee authorized to use teletherapy units for medical use shall perform output spot-checks on each teletherapy unit once in each calendar month that include determination of- (1) Timer accuracy, and timer linearity over the range of use; (2) On-off error; (3) The coincidence of the radiation and the field
thyroid carcinoma 35.940 Training for use of brachytherapy sources D N/A N/A 35.941 Training for ophthalmic use of strontium-90 D N/A N/A 35.950 Training for use of sealed sources for diagnosis D N/A N/A 35.960 Training for use of therapeutic medical devices D N/A N/A 35.961 Training for authorized medical physicist D N/A N/A 35.980 Training for an authorized nuclear pharmacist D N/A N/A 35.981 D N/A N/A
remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units 35.2610 Records of safety procedures D N/A N/A 35.2630 Records of dosimetry equipment used for remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units D N/A N/A 35.2632 Records of teletherapy, remote afterloader, and stereotactic D N/A N/A
radiosurgery full calibrations 35.2642 Records of periodic for teletherapy units D N/A N/A 35.2643 Records of periodic for remote afterloader units D N/A N/A 35.2645 Records of periodic for gamma stereotactic radiosurgery units D N/A N/A 35.2647 Records of additional technical requirements for mobile remote afterloader units D N/A N/A
(c) The licensee shall notify by telephone the NRC Operations 35.3067 Report of a leaking source C A licensee file a report within 5 days if a leak test required by 35.67 reveals the presence of 185 Bq ( 0.005 Ci) or more of removable contamination. The report must be filed with the appropriate NRC Regional Office listed in 30.6 of this chapter, by an appropriate method listed in 30.6(a), with a copy to the Director, Office of Nuclear Material Safety and Safeguards. The written report must include the model number and serial number if assigned, of the leaking source; the radionuclide and its estimated activity; the results of the test; the date of the test; and the action taken. 35.4001 Violations D N/A N/A 35.4002 Criminal penalties D N/A N/A